These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 37432545)

  • 1. Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation.
    Kotsopoulos J; Gronwald J; Huzarski T; Aeilts A; Randall Armel S; Karlan B; Singer CF; Eisen A; Tung N; Olopade O; Bordeleau L; Eng C; Foulkes WD; Neuhausen SL; Cullinane CA; Pal T; Fruscio R; Lubinski J; Metcalfe K; Sun P; Narod SA;
    Breast Cancer Res Treat; 2023 Sep; 201(2):257-264. PubMed ID: 37432545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.
    Phillips KA; Milne RL; Rookus MA; Daly MB; Antoniou AC; Peock S; Frost D; Easton DF; Ellis S; Friedlander ML; Buys SS; Andrieu N; Noguès C; Stoppa-Lyonnet D; Bonadona V; Pujol P; McLachlan SA; John EM; Hooning MJ; Seynaeve C; Tollenaar RA; Goldgar DE; Terry MB; Caldes T; Weideman PC; Andrulis IL; Singer CF; Birch K; Simard J; Southey MC; Olsson HL; Jakubowska A; Olah E; Gerdes AM; Foretova L; Hopper JL
    J Clin Oncol; 2013 Sep; 31(25):3091-9. PubMed ID: 23918944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group.
    Narod SA; Brunet JS; Ghadirian P; Robson M; Heimdal K; Neuhausen SL; Stoppa-Lyonnet D; Lerman C; Pasini B; de los Rios P; Weber B; Lynch H;
    Lancet; 2000 Dec; 356(9245):1876-81. PubMed ID: 11130383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis.
    Grann VR; Jacobson JS; Whang W; Hershman D; Heitjan DF; Antman KH; Neugut AI
    Cancer J Sci Am; 2000; 6(1):13-20. PubMed ID: 10696733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Nelson HD; Fu R; Zakher B; Pappas M; McDonagh M
    JAMA; 2019 Sep; 322(9):868-886. PubMed ID: 31479143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tamoxifen and risk of contralateral breast cancer among women with inherited mutations in BRCA1 and BRCA2: a meta-analysis.
    Xu L; Zhao Y; Chen Z; Wang Y; Chen L; Wang S
    Breast Cancer; 2015 Jul; 22(4):327-34. PubMed ID: 26022977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer.
    Reding KW; Bernstein JL; Langholz BM; Bernstein L; Haile RW; Begg CB; Lynch CF; Concannon P; Borg A; Teraoka SN; Törngren T; Diep A; Xue S; Bertelsen L; Liang X; Reiner AS; Capanu M; Malone KE;
    Breast Cancer Res Treat; 2010 Sep; 123(2):491-8. PubMed ID: 20135344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
    Gronwald J; Robidoux A; Kim-Sing C; Tung N; Lynch HT; Foulkes WD; Manoukian S; Ainsworth P; Neuhausen SL; Demsky R; Eisen A; Singer CF; Saal H; Senter L; Eng C; Weitzel J; Moller P; Gilchrist DM; Olopade O; Ginsburg O; Sun P; Huzarski T; Lubinski J; Narod SA;
    Breast Cancer Res Treat; 2014 Jul; 146(2):421-7. PubMed ID: 24951267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers.
    Metcalfe KA; Birenbaum-Carmeli D; Lubinski J; Gronwald J; Lynch H; Moller P; Ghadirian P; Foulkes WD; Klijn J; Friedman E; Kim-Sing C; Ainsworth P; Rosen B; Domchek S; Wagner T; Tung N; Manoukian S; Couch F; Sun P; Narod SA;
    Int J Cancer; 2008 May; 122(9):2017-22. PubMed ID: 18196574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Report of Endometrial Cancer in Australian BRCA1 and BRCA2 mutation-positive Families.
    Duffy DL; Antill YC; Stewart CJ; Young JP; ; Spurdle AB
    Twin Res Hum Genet; 2011 Apr; 14(2):111-8. PubMed ID: 21425892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
    Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S
    Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
    Kotsopoulos J; Lubinski J; Salmena L; Lynch HT; Kim-Sing C; Foulkes WD; Ghadirian P; Neuhausen SL; Demsky R; Tung N; Ainsworth P; Senter L; Eisen A; Eng C; Singer C; Ginsburg O; Blum J; Huzarski T; Poll A; Sun P; Narod SA;
    Breast Cancer Res; 2012 Mar; 14(2):R42. PubMed ID: 22405187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial.
    King MC; Wieand S; Hale K; Lee M; Walsh T; Owens K; Tait J; Ford L; Dunn BK; Costantino J; Wickerham L; Wolmark N; Fisher B;
    JAMA; 2001 Nov; 286(18):2251-6. PubMed ID: 11710890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
    Metcalfe K; Lynch HT; Ghadirian P; Tung N; Olivotto I; Warner E; Olopade OI; Eisen A; Weber B; McLennan J; Sun P; Foulkes WD; Narod SA
    J Clin Oncol; 2004 Jun; 22(12):2328-35. PubMed ID: 15197194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation.
    Metcalfe KA; Finch A; Poll A; Horsman D; Kim-Sing C; Scott J; Royer R; Sun P; Narod SA
    Br J Cancer; 2009 Jan; 100(2):421-5. PubMed ID: 19088722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
    Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
    JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.
    Kauff ND; Domchek SM; Friebel TM; Robson ME; Lee J; Garber JE; Isaacs C; Evans DG; Lynch H; Eeles RA; Neuhausen SL; Daly MB; Matloff E; Blum JL; Sabbatini P; Barakat RR; Hudis C; Norton L; Offit K; Rebbeck TR
    J Clin Oncol; 2008 Mar; 26(8):1331-7. PubMed ID: 18268356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
    Kotsopoulos J; Olopado OI; Ghadirian P; Lubinski J; Lynch HT; Isaacs C; Weber B; Kim-Sing C; Ainsworth P; Foulkes WD; Eisen A; Sun P; Narod SA
    Breast Cancer Res; 2005; 7(5):R833-43. PubMed ID: 16168130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report.
    Bernstein JL; Thomas DC; Shore RE; Robson M; Boice JD; Stovall M; Andersson M; Bernstein L; Malone KE; Reiner AS; Lynch CF; Capanu M; Smith SA; Tellhed L; Teraoka SN; Begg CB; Olsen JH; Mellemkjaer L; Liang X; Diep AT; Borg A; Concannon P; Haile RW;
    Eur J Cancer; 2013 Sep; 49(14):2979-85. PubMed ID: 23706288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers.
    Kotsopoulos J; Lubinski J; Lynch HT; Tung N; Armel S; Senter L; Singer CF; Fruscio R; Couch F; Weitzel JN; Karlan B; Foulkes WD; Moller P; Eisen A; Ainsworth P; Neuhausen SL; Olopade O; Sun P; Gronwald J; Narod SA;
    Breast Cancer Res Treat; 2019 Jun; 175(2):443-449. PubMed ID: 30756284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.